Compare Marathon Digital Holdings Inc (MARA) vs Moderna, Inc. (MRNA) Price & Performance

Marathon Digital Holdings (MARA) trades at $11.67, up 9.17% today, amid a strategic pivot from Bitcoin mining to AI infrastructure. Despite recent earnings misses and negative profitability metrics, the stock shows technical support near $10-11 levels. The company's acquisition of a 1,200-acre Texas site with 2 GW power capacity represents a significant expansion opportunity, though cash flow remains negative from operations.

MARA presents a high-risk opportunity with Wall Street analysts maintaining a 50% buy rating and $16.90 consensus target. The AI pivot could drive long-term growth, but investors face substantial execution risks amid persistent losses and negative cash flow. Near-term performance depends on successful business transformation and improved profitability.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.